Targeting Tumor Metabolism for Cancer Treatment: Is Pyruvate Dehydrogenase Kinases (PDKs) a Viable Anticancer Target?
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Cancer remains a lethal threat to global lives. Development of novel anticancer therapeutics is still a challenge to scientists in the field of biomedicine. In cancer cells, the metabolic features are significantly different from those of normal ones, which are hallmarks of several malignancies. Recent studies brought atypical cellular metabolism, such as aerobic glycolysis or the Warburg effect, into the scientific limelight. Targeting these altered metabolic pathways in cancer cells presents a promising therapeutic strategy. Pyruvate dehydrogenase kinases (PDKs), key enzymes in the pathway of glucose metabolism, could inactivate the pyruvate dehydrogenase complex (PDC) by phosphorylating it and preserving the substrates pyruvate, lactate and alanine for gluconeogenesis. Overexpression of PDKs could block the oxidative decarboxylation of pyruvate to satisfy high oxygen demand in cancer cells, while inhibition of PDKs could upregulate the activity of PDC and rectify the balance between the demand and supply of oxygen, which could lead to cancer cell death. Thus, inhibitors targeting PDKs represent a promising strategy for cancer treatment by acting on glycolytic tumors while showing minimal side effects on the oxidative healthy organs. This review considers the role of PDKs as regulator of PDC that catalyzes the oxidative decarboxylation of pyruvate in mitochondrion. It is concluded that PDKs are solid therapeutic targets. Inhibition of PDKs could be an attractive therapeutic approach for the development of anti-cancer drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Regulation of cancer cell metabolism
Cairns, R. A., Harris, I. S., & Mak, T. W. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2981 · Cited by 4,744 · cited 2×
“Glucose is metabolized to pyruvate, a critical checkpoint leading two distinct destinies: one is transformed to acetyl CoA by PDC and further oxidized via TCA cycle in the mitochondrion [32], the other is converted to lactate by LDHA in the cytoplasm [8].”
BackgroundThe metabolism of tumors in the body
Warburg, O., Wind, F., & Negelein, E. (1927) · Journal of General Physiology · doi:10.1085/jgp.8.6.519 · Cited by 4,416
Kim, J.-W., Tchernyshyov, I., Semenza, G. L., & Dang, C. V. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.02.002 · Cited by 3,905 · cited 2×
“HIF-1 also actively suppresses OXPHOS by trans-activating the genes encoding PDK1 [20,21] and 3 [50,51] directly which phosphorylate and inactivate PDC, thereby shunting pyruvate away from the TCA cycle by retarding its conversion to acetyl-CoA.”
BackgroundDang, C. V. (2012) · Cell · doi:10.1016/j.cell.2012.03.003 · Cited by 3,390
Aerobic glycolysis: Meeting the metabolic requirements of cell proliferation
Lunt, S. Y., & Vander Heiden, M. G. (2011) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-092910-154237 · Cited by 3,057
Tumor cell metabolism: cancer's Achilles' heel
Kroemer, G., & Pouyssegur, J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.05.005 · Cited by 2,337 · cited 1×
“PDC is a pivotal regulator of mitochondrial function, since it catalyzes the pyruvate decarboxylation and controls the amount of carbons derived from carbohydrate oxidized via TCA cycle [33,34].”
BackgroundHIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption
Papandreou, I., Cairns, R. A., Fontana, L., Lim, A. L., & Denko, N. C. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.012 · Cited by 2,267
Palsson-McDermott, E. M., Curtis, A. M., Goel, G., Lauterbach, M. A. R., Sheedy, F. J., Gleeson, L. E., van den Bosch, M. W. M., Quinn, S. R., Domingo-Fernandez, R., Johnston, D. G. W., et al. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2014.12.005 · Cited by 1,397
The Control of the Metabolic Switch in Cancers by Oncogenes and Tumor Suppressor Genes
Levine, A. J., & Puzio-Kuter, A. M. (2010) · Science · doi:10.1126/science.1193494 · Cited by 1,243
Kim, J.-W., Gao, P., Liu, Y.-C., Semenza, G. L., & Dang, C. V. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00440-07 · Cited by 658
Cited by
Metabolic reprogramming and epigenetic modifications on the path to cancer
Sun, L., Zhang, H., & Gao, P. (2022) · Protein & Cell · doi:10.1007/s13238-021-00846-7 · Cited by 770
ROS homeostasis and metabolism: a critical liaison for cancer therapy
Kim, J., Kim, J., & Bae, J.-S. (2016) · Experimental & Molecular Medicine · doi:10.1038/emm.2016.119 · Cited by 293
The metabolic landscape of lung cancer: New insights in a disturbed glucose metabolism
Vanhove, K., Graulus, G.-J., Mesotten, L., Thomeer, M., Derveaux, E., Noben, J.-P., Guedens, W., & Adriaensens, P. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01215 · Cited by 147
“PDK1 inhibits PDH by phosphorylation, resulting in increased conversion of pyruvate to lactate, and limiting the entry of glycolytic carbon substrates into the TCA cycle (95, 96).”
BackgroundO’Neill, S., Porter, R. K., McNamee, N., Martinez, V. G., & O’Driscoll, L. (2019) · Scientific Reports · doi:10.1038/s41598-019-39789-9 · Cited by 93
Differential response to exercise in claudin-low breast cancer
Glass, O. K., Bowie, M., Fuller, J., Darr, D., Usary, J., Boss, K., Choudhury, K. R., Liu, X., Zhang, Z., Locasale, J. W., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.21054 · Cited by 32
“Many studies are investigating the uses of targeted inhibitors of key metabolic pathways to reverse metabolic dysregulation of breast tumors [34].”
Background
Metadata
- Authors
- Zhang, W., Zhang, S.-L., Hu, X., & Tam, K. Y.
- Venue
- International Journal of Biological Sciences
- Publisher
- Ivyspring International Publisher
- Published
- 2015
- Volume
- 11
- Issue
- 12
- Pages
- 1390-1400
- ISSN
- 1449-2288 (ISSN-L)
- OpenAlex
- W2218000911
- Cited by
- 151
- References
- 18
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting Tumor Metabolism for Cancer Treatment: Is Pyruvate Dehydrogenase Kinases (PDKs) a Viable Anticancer Target? https://app.cochat.ai/papers/10.7150/ijbs.13325
- The paper
- Zhang, W., Zhang, S.-L., Hu, X., & Tam, K. Y. (2015). Targeting Tumor Metabolism for Cancer Treatment: Is Pyruvate Dehydrogenase Kinases (PDKs) a Viable Anticancer Target? International Journal of Biological Sciences. https://doi.org/10.7150/ijbs.13325
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.